[1]
Malaspina D, Owen MJ, Heckers S, Tandon R, Bustillo J, Schultz S, Barch DM, Gaebel W, Gur RE, Tsuang M, Van Os J, Carpenter W. Schizoaffective Disorder in the DSM-5. Schizophrenia research. 2013 Oct:150(1):21-5. doi: 10.1016/j.schres.2013.04.026. Epub 2013 May 23
[PubMed PMID: 23707642]
[2]
Wilson JE, Nian H, Heckers S. The schizoaffective disorder diagnosis: a conundrum in the clinical setting. European archives of psychiatry and clinical neuroscience. 2014 Feb:264(1):29-34. doi: 10.1007/s00406-013-0410-7. Epub 2013 Apr 27
[PubMed PMID: 23625467]
[3]
Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophrenia bulletin. 2009 Mar:35(2):383-402. doi: 10.1093/schbul/sbn135. Epub 2008 Nov 14
[PubMed PMID: 19011234]
[4]
Kendler KS, Gardner CO, Prescott CA. Toward a comprehensive developmental model for major depression in men. The American journal of psychiatry. 2006 Jan:163(1):115-24
[PubMed PMID: 16390898]
[5]
Laursen TM, Munk-Olsen T, Nordentoft M, Bo Mortensen P. A comparison of selected risk factors for unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia from a danish population-based cohort. The Journal of clinical psychiatry. 2007 Nov:68(11):1673-81
[PubMed PMID: 18052560]
[6]
Marneros A, Deister A, Rohde A. Psychopathological and social status of patients with affective, schizophrenic and schizoaffective disorders after long-term course. Acta psychiatrica Scandinavica. 1990 Nov:82(5):352-8
[PubMed PMID: 2281805]
[7]
Abrams DJ, Rojas DC, Arciniegas DB. Is schizoaffective disorder a distinct categorical diagnosis? A critical review of the literature. Neuropsychiatric disease and treatment. 2008 Dec:4(6):1089-109
[PubMed PMID: 19337453]
[8]
Azorin JM, Kaladjian A, Fakra E. [Current issues on schizoaffective disorder]. L'Encephale. 2005 May-Jun:31(3):359-65
[PubMed PMID: 16142051]
[9]
Meltzer HY, Arora RC, Metz J. Biological studies of schizoaffective disorders. Schizophrenia bulletin. 1984:10(1):49-70
[PubMed PMID: 6422546]
[10]
Antonius D, Prudent V, Rebani Y, D'Angelo D, Ardekani BA, Malaspina D, Hoptman MJ. White matter integrity and lack of insight in schizophrenia and schizoaffective disorder. Schizophrenia research. 2011 May:128(1-3):76-82. doi: 10.1016/j.schres.2011.02.020. Epub 2011 Mar 22
[PubMed PMID: 21429714]
[11]
Radonić E, Rados M, Kalember P, Bajs-Janović M, Folnegović-Smalc V, Henigsberg N. Comparison of hippocampal volumes in schizophrenia, schizoaffective and bipolar disorder. Collegium antropologicum. 2011 Jan:35 Suppl 1():249-52
[PubMed PMID: 21648342]
[12]
Smith MJ, Wang L, Cronenwett W, Mamah D, Barch DM, Csernansky JG. Thalamic morphology in schizophrenia and schizoaffective disorder. Journal of psychiatric research. 2011 Mar:45(3):378-85. doi: 10.1016/j.jpsychires.2010.08.003. Epub 2010 Aug 24
[PubMed PMID: 20797731]
[13]
Tandon R, Gaebel W, Barch DM, Bustillo J, Gur RE, Heckers S, Malaspina D, Owen MJ, Schultz S, Tsuang M, Van Os J, Carpenter W. Definition and description of schizophrenia in the DSM-5. Schizophrenia research. 2013 Oct:150(1):3-10. doi: 10.1016/j.schres.2013.05.028. Epub 2013 Jun 22
[PubMed PMID: 23800613]
[14]
Vieta E. Developing an individualized treatment plan for patients with schizoaffective disorder: from pharmacotherapy to psychoeducation. The Journal of clinical psychiatry. 2010:71 Suppl 2():14-9. doi: 10.4088/JCP.9096su1cc.03. Epub
[PubMed PMID: 21190648]
[15]
Cascade E, Kalali AH, Buckley P. Treatment of schizoaffective disorder. Psychiatry (Edgmont (Pa. : Township)). 2009 Mar:6(3):15-7
[PubMed PMID: 19724749]
[16]
Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. The Journal of clinical psychiatry. 2002 Sep:63(9):763-71
[PubMed PMID: 12363115]
[17]
Addington DE, Pantelis C, Dineen M, Benattia I, Romano SJ. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. The Journal of clinical psychiatry. 2004 Dec:65(12):1624-33
[PubMed PMID: 15641867]
Level 1 (high-level) evidence
[18]
Ciapparelli A, Dell'Osso L, Bandettini di Poggio A, Carmassi C, Cecconi D, Fenzi M, Chiavacci MC, Bottai M, Ramacciotti CE, Cassano GB. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. The Journal of clinical psychiatry. 2003 Apr:64(4):451-8
[PubMed PMID: 12716249]
[19]
Ghaemi SN, Goodwin FK. Use of atypical antipsychotic agents in bipolar and schizoaffective disorders: review of the empirical literature. Journal of clinical psychopharmacology. 1999 Aug:19(4):354-61
[PubMed PMID: 10440464]
[20]
Gunasekara NS, Spencer CM, Keating GM. Spotlight on ziprasidone in schizophrenia and schizoaffective disorder. CNS drugs. 2002:16(9):645-52
[PubMed PMID: 12153335]
[21]
Baethge C, Gruschka P, Berghöfer A, Bauer M, Müller-Oerlinghausen B, Bschor T, Smolka MN. Prophylaxis of schizoaffective disorder with lithium or carbamazepine: outcome after long-term follow-up. Journal of affective disorders. 2004 Apr:79(1-3):43-50
[PubMed PMID: 15023479]
[22]
Bogan AM, Brown ES, Suppes T. Efficacy of divalproex therapy for schizoaffective disorder. Journal of clinical psychopharmacology. 2000 Oct:20(5):520-2
[PubMed PMID: 11001235]
[23]
Dietrich DE, Kropp S, Emrich HM. [Oxcarbazepine in the treatment of affective and schizoaffective disorders]. Fortschritte der Neurologie-Psychiatrie. 2003 May:71(5):255-64
[PubMed PMID: 12740757]
[24]
Leucht S, McGrath J, White P, Kissling W. Carbamazepine for schizophrenia and schizoaffective psychoses. The Cochrane database of systematic reviews. 2002:(3):CD001258
[PubMed PMID: 12137621]
Level 1 (high-level) evidence
[25]
Koenig AM, Thase ME. First-line pharmacotherapies for depression - what is the best choice? Polskie Archiwum Medycyny Wewnetrznej. 2009 Jul-Aug:119(7-8):478-86
[PubMed PMID: 19776688]
[26]
McInerney SJ, Kennedy SH. Review of evidence for use of antidepressants in bipolar depression. The primary care companion for CNS disorders. 2014:16(5):. doi: 10.4088/PCC.14r01653. Epub 2014 Oct 16
[PubMed PMID: 25667812]
[27]
Fitzgerald P, de Castella A, Arya D, Simons WR, Eggleston A, Meere S, Kulkarni J. The cost of relapse in schizophrenia and schizoaffective disorder. Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists. 2009 Aug:17(4):265-72. doi: 10.1080/10398560903002998. Epub
[PubMed PMID: 19585288]
[28]
Pharoah FM, Rathbone J, Mari JJ, Streiner D. Family intervention for schizophrenia. The Cochrane database of systematic reviews. 2003:(4):CD000088
[PubMed PMID: 14583908]
Level 1 (high-level) evidence
[29]
Phutane VH, Thirthalli J, Kesavan M, Kumar NC, Gangadhar BN. Why do we prescribe ECT to schizophrenia patients? Indian journal of psychiatry. 2011 Apr:53(2):149-51. doi: 10.4103/0019-5545.82544. Epub
[PubMed PMID: 21772648]
[30]
Iancu I, Pick N, Seener-Lorsh O, Dannon P. Patients with schizophrenia or schizoaffective disorder who receive multiple electroconvulsive therapy sessions: characteristics, indications, and results. Neuropsychiatric disease and treatment. 2015:11():853-62. doi: 10.2147/NDT.S78919. Epub 2015 Mar 27
[PubMed PMID: 25848283]
[31]
Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC, Ganev K, Giel R, an der Heiden W, Holmberg SK, Janca A, Lee PW, León CA, Malhotra S, Marsella AJ, Nakane Y, Sartorius N, Shen Y, Skoda C, Thara R, Tsirkin SJ, Varma VK, Walsh D, Wiersma D. Recovery from psychotic illness: a 15- and 25-year international follow-up study. The British journal of psychiatry : the journal of mental science. 2001 Jun:178():506-17
[PubMed PMID: 11388966]
[32]
Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. Journal of psychopharmacology (Oxford, England). 2010 Nov:24(4 Suppl):81-90. doi: 10.1177/1359786810385490. Epub
[PubMed PMID: 20923923]
Level 1 (high-level) evidence
[33]
Suominen K, Isometsä E, Heilä H, Lönnqvist J, Henriksson M. General hospital suicides--a psychological autopsy study in Finland. General hospital psychiatry. 2002 Nov-Dec:24(6):412-6
[PubMed PMID: 12490343]
[34]
Stentzel U, van den Berg N, Schulze LN, Schwaneberg T, Radicke F, Langosch JM, Freyberger HJ, Hoffmann W, Grabe HJ. Predictors of medication adherence among patients with severe psychiatric disorders: findings from the baseline assessment of a randomized controlled trial (Tecla). BMC psychiatry. 2018 May 29:18(1):155. doi: 10.1186/s12888-018-1737-4. Epub 2018 May 29
[PubMed PMID: 29843676]
Level 1 (high-level) evidence